SLSiyan Liu

Siyan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siyan Liu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Hua Xing

    Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, China

    1 shared publication
  • Jing Li

    Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People’s Republic of China

    1 shared publication
  • Kunzhe Wu

    Department of Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, People’s Republic of China

    1 shared publication
  • Lin Gu

    Breast Surgery, Jilin Province Tumor Hospital, Changchun, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer

    by Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing

    Triple-negative breast cancer (TNBC) exhibits high recurrence and mortality rates because of the lack of effective treatment targets. Surgery and traditional chemotherapy are the primary treatment options. Immunotherapy shows high potential for treating various cancers but exhibits limited efficacy against TNBC as a monotherapy. Chemoimmunotherapy has broad prospects for applications for cancer treatment conferred through the synergistic immunomodulatory and anti-tumor effects of chemotherapy and immunotherapeutic strategies. However, improving the efficacy of synergistic therapy and reducing the side effects of multiple drugs remain to be the main challenges in chemoimmunotherapy against TNBC. Nanocarriers can target both cancer and immune cells, promote drug accumulation, and show minimal toxicity, making them ideal delivery systems for chemotherapeutic and immunotherapeutic agents. In this review, we introduce the immunomodulatory effects of chemotherapy and combined mechanisms of chemoimmunotherapy, followed by a summary of nanoparticle-mediated chemoimmunotherapeutic strategies used for treating TNBC. This up-to-date synthesis of relevant findings in the field merits contemplation, while considering avenues of investigation to enable advances in the field.